Harrow reported second-quarter revenue of $70.7 million, an 11% increase year over year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The company reiterated its full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. Management expects second-half growth from improved VEVYE pricing and expanded commercial coverage, IHEEZO's 25% net price increase, BYOOVIZ and the relaunch of VERKAZIA. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, with more than $30 million of revenue expected in 2027 if the deal closes. The company also advanced pipeline programs G-MELT and YOCHIL, targeting future FDA submissions.
Harrow Health IncQ2 revenue up 11% and reiterated guidance, plus planned acquisition of TYRVAYA rights.
